Path Fertility Wins $2M NIH Grant for Male Infertility

Two years of fertility treatment and roughly $80K in spending left a couple with an explanation that explained very little. Path Fertility describes that experience, shared by friends of its founders in 2018, as part of the reason it began developing a deeper assessment of male fertility. The business grew around a consequential imbalance: a couple could keep moving through treatment while the information about the male partner remained incomplete.

The Salt Lake City molecular diagnostics company now has federal support for research into severe male infertility. In an October 26, 2026 announcement, Path Fertility, the commercial brand of Inherent Biosciences, disclosed a two-year, $2M Direct to Phase II Small Business Innovation Research grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the NIH. The award funds development and clinical validation of an epigenetic diagnostic for non-obstructive azoospermia, or NOA, alongside investigation of associated cancer risk.

For co-founders Andy Olson, CEO, and Kristin Brogaard, PhD, CSO, the commercial question runs through a clinical conversation: can a test give a physician useful information before a patient makes a difficult treatment choice? Brogaard is the award's principal investigator. The new program extends the company's work from sperm-quality assessment toward a group of men facing especially limited answers about their infertility.

What Path Fertility's $2M grant will fund

The announced research centers on epigenetic changes in MSH5, a DNA-repair gene. Path Fertility plans to investigate the marker across multiple clinical sites, develop a semen-based reflex assay, and validate the assay in a CLIA-certified laboratory. It also plans to examine MSH5 epimutations in 500 patients with colorectal cancer, giving the program a broader research question about the relationship between reproductive biology and health.

Path intends to incorporate the assay into NOA Guide, its platform for assessing the likelihood of surgical sperm retrieval in men with NOA. The proposed MSH5 assay remains in development, and the cancer component is an investigation rather than an established screening service. A research objective carries a different clinical meaning from a validated result that a physician can already use.

The financing structure matters to the company's operating plan. NIH's small-business programs support early-stage research and development with non-dilutive capital. This grant finances a defined scientific program without establishing an equity price for Path Fertility or making NIH a commercial customer. Its two-year scope gives the team work to organize across assay development, study execution and laboratory validation, each with its own evidence requirements before broader use.

The diagnostic business begins before the next procedure

Path Fertility's existing SpermQT product examines DNA methylation patterns associated with sperm function. Its science overview distinguishes that measurement from conventional semen analysis, which examines visible characteristics, and from DNA-fragmentation testing. The company's position is that additional biological information can improve the discussion about a couple's treatment options. That proposition puts the value of the report close to the decision being considered.

The company already has an ordering route into fertility practices. Its provider instructions describe physician-ordered SpermQT testing with collection at home or in a clinical setting. Samples move to a laboratory, and a result returns to a clinician who has to interpret it in the context of the patient. Collection convenience and laboratory analysis are therefore parts of one continuing service relationship, rather than separate selling points.

For a clinic, an additional test also means an additional explanation. The physician has to establish what the measurement adds, how confidently it applies to the patient, and whether it changes the available choices. Those are practical adoption questions for any diagnostics business. Path Fertility's grant-funded work will have to join that existing workflow with evidence specific to NOA, where the clinical problem differs from the population studied with SpermQT.

Clinical evidence needs its population attached

A peer-reviewed study published in January 2026 examined SpermQT results and real-world outcomes from 537 couples across 10 US fertility clinics. Among 202 couples with documented intrauterine insemination outcomes, the study reported a 22% cumulative pregnancy rate in the normal-result group and no pregnancies among the 25 couples in the abnormal-result group. The finding describes the outcomes observed in that cohort, with a small abnormal-result subgroup.

The paper's retrospective design, discretionary ordering and incomplete clinical information limit how far the result travels. Its participants also excluded azoospermic men. That makes the distinction especially relevant to the new grant: evidence about SpermQT and IUI cannot simply be carried over to a proposed NOA assay. Each test has to earn the clinical interpretation attached to its own population and intended use.

For readers following diagnostics companies, this is where commercial shorthand can get expensive. A laboratory measurement, a statistical association and a treatment decision sit at different points in the evidence chain. Keeping those points visible helps explain why a company with an existing product still needs targeted research to extend its platform. The new capital supports that extension while the underlying clinical questions remain specific to the assay under development.

Building a company around an answer clinicians can use

Olson's background in molecular diagnostics and Brogaard's work in epigenetics give Path Fertility complementary commercial and scientific leadership, according to the company's founder biographies. Their task spans the distance between observing biology and giving a clinician a result worth discussing. The company's own origin account places the burden of unresolved infertility inside that distance, including the treatments a couple may already have undergone.

Path's parent-company newsroom also records an earlier $1.9M NIH Fast-Track grant announced in 2023. That history shows federal research support preceding the current program, although it should not be turned into an assumed lifetime financing total. Private investment, project awards and annual government obligations answer different accounting questions, and the new announcement supplies no company valuation.

The immediate development path is concrete enough to follow: additional clinical sites, an assay that can work from semen, and laboratory validation for the intended application. For Path Fertility, the work continues toward the moment a reproductive urologist can put a report in front of a patient and explain what it adds to the decision about surgery. The grant places funding behind the research needed to make that conversation more informative.